The Cardiovascular Impact of Carfilzomib in Multiple Myeloma

被引：0
|
作者：
Rosenthal, Allison C. [1 ]
Luthi, Jennifer [1 ]
Belohlavek, Marek [1 ]
Mookadam, Farouk [1 ]
Mayo, Angela [1 ]
Fonseca, Rafael [1 ,2 ]
Bergsagel, P. Leif
Reeder, Craig B. [1 ]
Mikhael, Joseph R. [1 ]
Stewart, Keith [2 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Global deterioration of cardiovascular mechanics by carfilzomib treatment is associated with proteasome activity in patients with relapsed multiple myeloma
    Makris, N.
    Laina, A.
    Georgiopoulos, G.
    Gavriatopoulou, M.
    Papanagnou, E. D.
    Eleutherakis-Papaiakovou, E.
    Fotiou, D.
    Dialoupi, I.
    Migkou, M.
    Roussou, M.
    Terpos, E.
    Trougakos, I. P.
    Dimopoulos, M. A.
    Kastritis, E.
    Stamatelopoulos, K.
    EUROPEAN HEART JOURNAL, 2021, 42 : 749 - 749
  • [32] The role of carfilzomib in treatment of newly diagnosed multiple myeloma
    Strifler, Susanne
    Knop, Stefan
    FUTURE ONCOLOGY, 2018, 14 (30) : 3123 - 3134
  • [33] New drugs in multiple myeloma - role of carfilzomib and pomalidomide
    Jurczyszyn, Artur
    Legiec, Wojciech
    Helbig, Grzegorz
    Hus, Marek
    Kyrcz-Krzemien, Slawomira
    Skotnicki, Aleksander B.
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (01): : 17 - 21
  • [34] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
    Fostier, Karel
    De Becker, Ann
    Schots, Rik
    ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
  • [35] Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
    Boccon-Gibod, Clementine
    Talbot, Alexis
    Le Bras, Fabien
    Frenzel, Laurent
    Royer, Bruno
    Harel, Stephanie
    Lombion, Naelle
    Belhadj, Karim
    Cuccuini, Wendy
    Arnulf, Bertrand
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : E73 - E76
  • [36] Pancreatic Hyperamylasemia and Hyperlipasemia Associated With Carfilzomib in Multiple Myeloma
    Nakamura, Yuichi
    Okuda, Itoko
    Uchida, Yumiko
    Ito, Yoshihiro
    Wakimoto, Naoki
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (10) : 1067 - 1068
  • [37] Echocardiographic Changes of Carfilzomib Therapy in Multiple Myeloma Patients
    Bahaj, Waled
    Albawaliz, Anas
    Begemann, Madeline E.
    Shrestha, Anuj
    Sperry, Brett
    Raza, Shahzad
    BLOOD, 2020, 136
  • [38] Carfilzomib/pomalidomideLack of efficacy in multiple myeloma: case report
    Reactions Weekly, 2021, 1871 (1) : 114 - 114
  • [39] Managing Adverse Events of Multiple Myeloma and Anti-Multiple Myeloma Treatment: A Perspective on Carfilzomib
    Siegel, David S.
    ONCOLOGY-NEW YORK, 2013, 27 : 2 - 3
  • [40] Targeted treatments for multiple myeloma: specific role of carfilzomib
    Sugumar, Dhivya
    Keller, Jesse
    Vij, Ravi
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 23 - 33
12345